Macular Edema clinical trials at UCSF
2 in progress, 1 open to eligible people
Video Intervention to Improve Understanding of Diabetic Retinopathy at Zuckerberg San Francisco General Hospital and Trauma Center
open to eligible people ages 18 years and up
The study will evaluate whether videos can improve understanding of diabetic eye disease, and follow-up rates in the eye clinic.
San Francisco, California
Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
Sorry, in progress, not accepting new patients
This study will evaluate the efficacy, safety, and Pharmacokinetics (PK) of the PDS with ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal (IVT) ranibizumab 0.5 milligrams (mg) every 4 weeks (Q4W). The substudy will evaluate safety of re-implanting the updated PDS with ranibizumab and the refill-exchange procedures following re-implantation in participants with DME who were previously enrolled in the main study, GR40550. Up to 100 participants from the main study will be enrolled and followed for a maximum of 72 weeks post-re-implantation in the substudy.
San Francisco, California and other locations
Our lead scientists for Macular Edema research studies include Sriranjani Padmanabhan, MD.
Last updated: